VJHemOnc is committed to improving our service to you

ASH 2015 | Treatment of relapsed multiple myeloma: New combinations, new generations, new targets

VJHemOnc is committed to improving our service to you

Keith Stewart

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale, AZ, summarises recently approved treatment options for patients with relapsed multiple myeloma, including proteasome inhibitors, carfilzomib and ixazomib; histone deacetylase (HDAC) inhibitor, panobinostat; and monoclonal antibodies, CS1-targeting elotuzumab and CD38-targeting daratumumab.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter